National Institutes of Health's Center for Cancer Research: Clinical Trial Researching Combination Drug Therapy for Ewing Sarcoma and Rhabdomyosarcoma
November 05, 2024
November 05, 2024
BETHESDA, Maryland, Nov. 5 (TNSres) -- The National Institutes of Health's Center for Cancer Research issued the following news:
The drug PEN-866 can remain in tumor cells longer than it does in normal cells. It also may be more effective than other drugs at treating Ewing sarcoma and rhabdomyosarcoma.
A clinical trial led by Christine M. Heske, M.D., Investigator in the Pediatric Oncology Branch, is researching PEN-866 in combination with vincristine and temozolomide f . . .
The drug PEN-866 can remain in tumor cells longer than it does in normal cells. It also may be more effective than other drugs at treating Ewing sarcoma and rhabdomyosarcoma.
A clinical trial led by Christine M. Heske, M.D., Investigator in the Pediatric Oncology Branch, is researching PEN-866 in combination with vincristine and temozolomide f . . .